{"entity":{"type":"insider","cik":"0001687880","url":"/insider/0001687880","json_url":"/insider/0001687880.json","name":"Versant Venture Capital VI, L.P.","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":186,"n_filings":51,"first":"2019-06-25","last":"2025-10-02","span_basis":"filed_date"},"name_variants":[{"name":"Versant Venture Capital VI, L.P.","source":"filing","n_filings":51,"first_seen":"2019-06-25","last_seen":"2025-10-02"}],"transactions":[{"id":4171160,"accession":"0001193125-25-228493","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001193125-25-228493","line_url":"/filing/0001193125-25-228493","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"LENZ Therapeutics, Inc.","issuer_ticker":"LENZ","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage II GP, L.P.; Versant Vantage II GP-GP, LLC; Versant Vantage II, L.P.; Versant Venture Capital VI, L.P.; Versant Venture Capital VII, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC; Versant Ventures VII GP, L.P.; Versant Ventures VII GP-GP, LLC","owner_display_name":"Versant Vantage II GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":224974.0,"shares_display":"224,974","price_per_share":46.01428365322215,"price_display":"46.01","price_state":"stated","total_value":10352017.4506,"total_display":"10,352,017.45","total_whole":"10,352,017","shares_owned_after":1050776.0,"shares_owned_after_display":"1,050,776","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-30","filed_date":"2025-10-02","scope":"insider","n_lines":6},{"id":5025160,"accession":"0001193125-25-213445","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-25-213445","line_url":"/filing/0001193125-25-213445","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"LAVA Therapeutics NV","issuer_ticker":"LVTX","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage I GP, L.P.; Versant Vantage I GP-GP, LLC; Versant Vantage I, L.P.; Versant Venture Capital VI, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC","owner_display_name":"Versant Vantage I GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2903403.0,"shares_display":"2,903,403","price_per_share":1.4014,"price_display":"1.40","price_state":"stated","total_value":4068828.9642,"total_display":"4,068,828.96","total_whole":"4,068,829","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-19","filed_date":"2025-09-23","scope":"insider","n_lines":2},{"id":4990228,"accession":"0001193125-25-207677","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001193125-25-207677","line_url":"/filing/0001193125-25-207677","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"LAVA Therapeutics NV","issuer_ticker":"LVTX","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage I GP, L.P.; Versant Vantage I GP-GP, LLC; Versant Vantage I, L.P.; Versant Venture Capital VI, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC","owner_display_name":"Versant Vantage I GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":594902.0,"shares_display":"594,902","price_per_share":1.4418,"price_display":"1.44","price_state":"stated","total_value":857729.7036,"total_display":"857,729.70","total_whole":"857,730","shares_owned_after":2370533.0,"shares_owned_after_display":"2,370,533","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-18","filed_date":"2025-09-18","scope":"insider","n_lines":2},{"id":4456153,"accession":"0001193125-25-211363","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001193125-25-211363","line_url":"/filing/0001193125-25-211363","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"LENZ Therapeutics, Inc.","issuer_ticker":"LENZ","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage II GP, L.P.; Versant Vantage II GP-GP, LLC; Versant Vantage II, L.P.; Versant Venture Capital VI, L.P.; Versant Venture Capital VII, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC; Versant Ventures VII GP, L.P.; Versant Ventures VII GP-GP, LLC","owner_display_name":"Versant Vantage II GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":135304.0,"shares_display":"135,304","price_per_share":42.233459455744104,"price_display":"42.23","price_state":"stated","total_value":5714355.9982,"total_display":"5,714,356.00","total_whole":"5,714,356","shares_owned_after":1224718.0,"shares_owned_after_display":"1,224,718","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-18","filed_date":"2025-09-22","scope":"insider","n_lines":6},{"id":4990217,"accession":"0001193125-25-207677","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001193125-25-207677","line_url":"/filing/0001193125-25-207677","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"LAVA Therapeutics NV","issuer_ticker":"LVTX","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage I GP, L.P.; Versant Vantage I GP-GP, LLC; Versant Vantage I, L.P.; Versant Venture Capital VI, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC","owner_display_name":"Versant Vantage I GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":589532.0,"shares_display":"589,532","price_per_share":1.4892,"price_display":"1.49","price_state":"stated","total_value":877931.0544,"total_display":"877,931.05","total_whole":"877,931","shares_owned_after":2736644.0,"shares_owned_after_display":"2,736,644","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-17","filed_date":"2025-09-18","scope":"insider","n_lines":2},{"id":4990207,"accession":"0001193125-25-207677","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001193125-25-207677","line_url":"/filing/0001193125-25-207677","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"LAVA Therapeutics NV","issuer_ticker":"LVTX","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage I GP, L.P.; Versant Vantage I GP-GP, LLC; Versant Vantage I, L.P.; Versant Venture Capital VI, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC","owner_display_name":"Versant Vantage I GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500000.0,"shares_display":"500,000","price_per_share":1.5332,"price_display":"1.53","price_state":"stated","total_value":766600.0,"total_display":"766,600.00","total_whole":"766,600","shares_owned_after":3099450.0,"shares_owned_after_display":"3,099,450","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-09-16","filed_date":"2025-09-18","scope":"insider","n_lines":2},{"id":4419379,"accession":"0000950170-25-111529","txn_seq":12,"anchor":"line-12","filing_url":"/filing/0000950170-25-111529","line_url":"/filing/0000950170-25-111529","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"LENZ Therapeutics, Inc.","issuer_ticker":"LENZ","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage II GP, L.P.; Versant Vantage II GP-GP, LLC; Versant Vantage II, L.P.; Versant Venture Capital VI, L.P.; Versant Venture Capital VII, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC; Versant Ventures VII GP, L.P.; Versant Ventures VII GP-GP, LLC","owner_display_name":"Versant Vantage II GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":70811.0,"shares_display":"70,811","price_per_share":39.01295024784285,"price_display":"39.01","price_state":"stated","total_value":2762546.02,"total_display":"2,762,546.02","total_whole":"2,762,546","shares_owned_after":1277662.0,"shares_owned_after_display":"1,277,662","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-26","filed_date":"2025-08-26","scope":"insider","n_lines":4},{"id":4419360,"accession":"0000950170-25-111529","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0000950170-25-111529","line_url":"/filing/0000950170-25-111529","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"LENZ Therapeutics, Inc.","issuer_ticker":"LENZ","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage II GP, L.P.; Versant Vantage II GP-GP, LLC; Versant Vantage II, L.P.; Versant Venture Capital VI, L.P.; Versant Venture Capital VII, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC; Versant Ventures VII GP, L.P.; Versant Ventures VII GP-GP, LLC","owner_display_name":"Versant Vantage II GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":78237.0,"shares_display":"78,237","price_per_share":39.54172007362246,"price_display":"39.54","price_state":"stated","total_value":3093625.5534,"total_display":"3,093,625.55","total_whole":"3,093,626","shares_owned_after":1323789.0,"shares_owned_after_display":"1,323,789","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-25","filed_date":"2025-08-26","scope":"insider","n_lines":4},{"id":4419339,"accession":"0000950170-25-111529","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-25-111529","line_url":"/filing/0000950170-25-111529","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"LENZ Therapeutics, Inc.","issuer_ticker":"LENZ","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage II GP, L.P.; Versant Vantage II GP-GP, LLC; Versant Vantage II, L.P.; Versant Venture Capital VI, L.P.; Versant Venture Capital VII, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC; Versant Ventures VII GP, L.P.; Versant Ventures VII GP-GP, LLC","owner_display_name":"Versant Vantage II GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":39046.0,"shares_display":"39,046","price_per_share":40.15132104697024,"price_display":"40.15","price_state":"stated","total_value":1567748.4816,"total_display":"1,567,748.48","total_whole":"1,567,748","shares_owned_after":1379727.0,"shares_owned_after_display":"1,379,727","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-22","filed_date":"2025-08-26","scope":"insider","n_lines":4},{"id":4947847,"accession":"0000950170-25-110163","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0000950170-25-110163","line_url":"/filing/0000950170-25-110163","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"LENZ Therapeutics, Inc.","issuer_ticker":"LENZ","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage II GP, L.P.; Versant Vantage II GP-GP, LLC; Versant Vantage II, L.P.; Versant Venture Capital VI, L.P.; Versant Venture Capital VII, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC; Versant Ventures VII GP, L.P.; Versant Ventures VII GP-GP, LLC","owner_display_name":"Versant Vantage II GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":45713.0,"shares_display":"45,713","price_per_share":38.5611,"price_display":"38.56","price_state":"stated","total_value":1762743.5643,"total_display":"1,762,743.56","total_whole":"1,762,744","shares_owned_after":1400220.0,"shares_owned_after_display":"1,400,220","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-18","filed_date":"2025-08-19","scope":"insider","n_lines":2},{"id":4947836,"accession":"0000950170-25-110163","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-25-110163","line_url":"/filing/0000950170-25-110163","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"LENZ Therapeutics, Inc.","issuer_ticker":"LENZ","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage II GP, L.P.; Versant Vantage II GP-GP, LLC; Versant Vantage II, L.P.; Versant Venture Capital VI, L.P.; Versant Venture Capital VII, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC; Versant Ventures VII GP, L.P.; Versant Ventures VII GP-GP, LLC","owner_display_name":"Versant Vantage II GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":215000.0,"shares_display":"215,000","price_per_share":39.5,"price_display":"39.50","price_state":"stated","total_value":8492500.0,"total_display":"8,492,500.00","total_whole":"8,492,500","shares_owned_after":1430848.0,"shares_owned_after_display":"1,430,848","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-08-15","filed_date":"2025-08-19","scope":"insider","n_lines":2},{"id":5198366,"accession":"0000950170-25-095616","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-095616","line_url":"/filing/0000950170-25-095616#line-1","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"LENZ Therapeutics, Inc.","issuer_ticker":"LENZ","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage II GP, L.P.; Versant Vantage II GP-GP, LLC; Versant Vantage II, L.P.; Versant Venture Capital VI, L.P.; Versant Venture Capital VII, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC; Versant Ventures VII GP, L.P.; Versant Ventures VII GP-GP, LLC","owner_display_name":"Versant Vantage II GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":191376.0,"shares_display":"191,376","price_per_share":34.0,"price_display":"34.00","price_state":"stated","total_value":6506784.0,"total_display":"6,506,784.00","total_whole":"6,506,784","shares_owned_after":1575899.0,"shares_owned_after_display":"1,575,899","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-07-10","filed_date":"2025-07-14","scope":"insider"},{"id":4836463,"accession":"0000950170-25-092373","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-092373","line_url":"/filing/0000950170-25-092373#line-1","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"LENZ Therapeutics, Inc.","issuer_ticker":"LENZ","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage II GP, L.P.; Versant Vantage II GP-GP, LLC; Versant Vantage II, L.P.; Versant Venture Capital VI, L.P.; Versant Venture Capital VII, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC; Versant Ventures VII GP, L.P.; Versant Ventures VII GP-GP, LLC","owner_display_name":"Versant Vantage II GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":200000.0,"shares_display":"200,000","price_per_share":30.465,"price_display":"30.46","price_state":"stated","total_value":6093000.0,"total_display":"6,093,000.00","total_whole":"6,093,000","shares_owned_after":1767275.0,"shares_owned_after_display":"1,767,275","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-27","filed_date":"2025-07-01","scope":"insider"},{"id":4063046,"accession":"0000950170-25-088604","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-25-088604","line_url":"/filing/0000950170-25-088604","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"LENZ Therapeutics, Inc.","issuer_ticker":"LENZ","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage II GP, L.P.; Versant Vantage II GP-GP, LLC; Versant Vantage II, L.P.; Versant Venture Capital VI, L.P.; Versant Venture Capital VII, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC; Versant Ventures VII GP, L.P.; Versant Ventures VII GP-GP, LLC","owner_display_name":"Versant Vantage II GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":234801.0,"shares_display":"234,801","price_per_share":30.2929627642131,"price_display":"30.29","price_state":"stated","total_value":7112817.95,"total_display":"7,112,817.95","total_whole":"7,112,818","shares_owned_after":1967275.0,"shares_owned_after_display":"1,967,275","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-06-20","filed_date":"2025-06-20","scope":"insider","n_lines":2},{"id":4063040,"accession":"0000950170-25-088604","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-088604","line_url":"/filing/0000950170-25-088604#line-1","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"LENZ Therapeutics, Inc.","issuer_ticker":"LENZ","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage II GP, L.P.; Versant Vantage II GP-GP, LLC; Versant Vantage II, L.P.; Versant Venture Capital VI, L.P.; Versant Venture Capital VII, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC; Versant Ventures VII GP, L.P.; Versant Ventures VII GP-GP, LLC","owner_display_name":"Versant Vantage II GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100000.0,"shares_display":"100,000","price_per_share":29.95,"price_display":"29.95","price_state":"stated","total_value":2995000.0,"total_display":"2,995,000.00","total_whole":"2,995,000","shares_owned_after":1148789.0,"shares_owned_after_display":"1,148,789","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-06-18","filed_date":"2025-06-20","scope":"insider"},{"id":4264480,"accession":"0000950170-25-085490","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-085490","line_url":"/filing/0000950170-25-085490#line-1","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"LENZ Therapeutics, Inc.","issuer_ticker":"LENZ","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage II GP, L.P.; Versant Vantage II GP-GP, LLC; Versant Vantage II, L.P.; Versant Venture Capital VI, L.P.; Versant Venture Capital VII, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC; Versant Ventures VII GP, L.P.; Versant Ventures VII GP-GP, LLC","owner_display_name":"Versant Vantage II GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":9,"other_reporting_owners":8,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":350000.0,"shares_display":"350,000","price_per_share":29.0,"price_display":"29.00","price_state":"stated","total_value":10150000.0,"total_display":"10,150,000.00","total_whole":"10,150,000","shares_owned_after":1248789.0,"shares_owned_after_display":"1,248,789","ownership_form":"I","is_10b5_1":null,"transaction_date":"2025-06-10","filed_date":"2025-06-12","scope":"insider"},{"id":3112863,"accession":"0000950170-24-119051","txn_seq":13,"anchor":"line-13","filing_url":"/filing/0000950170-24-119051","line_url":"/filing/0000950170-24-119051","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"Monte Rosa Therapeutics, Inc.","issuer_ticker":"GLUE","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage I GP, L.P.; Versant Vantage I GP-GP, LLC; Versant Vantage I, L.P.; Versant Venture Capital VI, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC","owner_display_name":"Versant Vantage I GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":67905.0,"shares_display":"67,905","price_per_share":9.15692125027612,"price_display":"9.16","price_state":"stated","total_value":621800.7375,"total_display":"621,800.74","total_whole":"621,801","shares_owned_after":1589053.0,"shares_owned_after_display":"1,589,053","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-10-29","filed_date":"2024-10-30","scope":"insider","n_lines":2},{"id":3112856,"accession":"0000950170-24-119051","txn_seq":11,"anchor":"line-11","filing_url":"/filing/0000950170-24-119051","line_url":"/filing/0000950170-24-119051#line-11","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"Monte Rosa Therapeutics, Inc.","issuer_ticker":"GLUE","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage I GP, L.P.; Versant Vantage I GP-GP, LLC; Versant Vantage I, L.P.; Versant Venture Capital VI, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC","owner_display_name":"Versant Vantage I GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":89990.0,"shares_display":"89,990","price_per_share":9.6593,"price_display":"9.66","price_state":"stated","total_value":869240.407,"total_display":"869,240.41","total_whole":"869,240","shares_owned_after":2007948.0,"shares_owned_after_display":"2,007,948","ownership_form":"I","is_10b5_1":null,"transaction_date":"2024-10-28","filed_date":"2024-10-30","scope":"insider"},{"id":2083039,"accession":"0000950170-24-109112","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-109112","line_url":"/filing/0000950170-24-109112#line-1","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"Monte Rosa Therapeutics, Inc.","issuer_ticker":"GLUE","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage I GP, L.P.; Versant Vantage I GP-GP, LLC; Versant Vantage I, L.P.; Versant Venture Capital VI, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC","owner_display_name":"Versant Vantage I GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1132566.0,"shares_display":"1,132,566","price_per_share":6.5296,"price_display":"6.53","price_state":"stated","total_value":7395202.9536,"total_display":"7,395,202.95","total_whole":"7,395,203","shares_owned_after":5099336.0,"shares_owned_after_display":"5,099,336","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-20","filed_date":"2024-09-24","scope":"insider"},{"id":2897808,"accession":"0000950170-24-106532","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0000950170-24-106532","line_url":"/filing/0000950170-24-106532#line-3","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"Monte Rosa Therapeutics, Inc.","issuer_ticker":"GLUE","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage I GP, L.P.; Versant Vantage I GP-GP, LLC; Versant Vantage I, L.P.; Versant Venture Capital VI, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC","owner_display_name":"Versant Vantage I GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9269.0,"shares_display":"9,269","price_per_share":6.1603,"price_display":"6.16","price_state":"stated","total_value":57099.8207,"total_display":"57,099.82","total_whole":"57,100","shares_owned_after":6231902.0,"shares_owned_after_display":"6,231,902","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-13","filed_date":"2024-09-13","scope":"insider"},{"id":2897804,"accession":"0000950170-24-106532","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0000950170-24-106532","line_url":"/filing/0000950170-24-106532#line-2","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"Monte Rosa Therapeutics, Inc.","issuer_ticker":"GLUE","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage I GP, L.P.; Versant Vantage I GP-GP, LLC; Versant Vantage I, L.P.; Versant Venture Capital VI, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC","owner_display_name":"Versant Vantage I GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":16047.0,"shares_display":"16,047","price_per_share":6.0017,"price_display":"6.00","price_state":"stated","total_value":96309.2799,"total_display":"96,309.28","total_whole":"96,309","shares_owned_after":6241171.0,"shares_owned_after_display":"6,241,171","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-12","filed_date":"2024-09-13","scope":"insider"},{"id":2897797,"accession":"0000950170-24-106532","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-106532","line_url":"/filing/0000950170-24-106532#line-1","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"Monte Rosa Therapeutics, Inc.","issuer_ticker":"GLUE","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage I GP, L.P.; Versant Vantage I GP-GP, LLC; Versant Vantage I, L.P.; Versant Venture Capital VI, L.P.; Versant Ventures VI GP, L.P.; Versant Ventures VI GP-GP, LLC","owner_display_name":"Versant Vantage I GP, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":6,"other_reporting_owners":5,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":541897.0,"shares_display":"541,897","price_per_share":6.0,"price_display":"6.00","price_state":"stated","total_value":3251382.0,"total_display":"3,251,382.00","total_whole":"3,251,382","shares_owned_after":6257218.0,"shares_owned_after_display":"6,257,218","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-09-11","filed_date":"2024-09-13","scope":"insider"},{"id":2389239,"accession":"0000950170-24-102354","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-102354","line_url":"/filing/0000950170-24-102354#line-1","is_derivative":false,"issuer_cik":"0001687880","issuer_name":"Black Diamond Therapeutics, Inc.","issuer_ticker":"BDTX","issuer_name_source":null,"issuer_url":"/issuer/0001687880","owner_cik":null,"owner_name":"Versant Vantage I, L.P.; Versant Venture Capital VI, L.P.; Versant Voyageurs I Parallel, L.P.; Versant Voyageurs I, L.P.","owner_display_name":"Versant Vantage I, L.P.","owner_url":null,"role":"Ten percent owner","role_mark":null,"role_mark_label":"Not attributed","role_mark_generic":"Not stated","n_reporting_owners":4,"other_reporting_owners":3,"officer_title":null,"security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":221600.0,"shares_display":"221,600","price_per_share":6.3202,"price_display":"6.32","price_state":"stated","total_value":1400556.32,"total_display":"1,400,556.32","total_whole":"1,400,556","shares_owned_after":3726341.0,"shares_owned_after_display":"3,726,341","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-08-28","filed_date":"2024-08-30","scope":"insider"}],"collapsed":true,"next_cursor":"2024-08-28|2389239","ledger_fault":false,"count":{"value":13,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":1,"open_market":true},{"code":"S","label":"Open-market sale","n":12,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":13},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001815776","name":"LENZ Therapeutics, Inc.","url":"/issuer/0001815776","role":"Ten percent owner","n_filings":9,"first_seen":"2021-07-01","last_seen":"2025-10-02"},{"type":"issuer","type_label":"ISSUER","cik":"0001840748","name":"LAVA Therapeutics NV","url":"/issuer/0001840748","role":"Ten percent owner","n_filings":2,"first_seen":"2025-09-18","last_seen":"2025-09-23"},{"type":"issuer","type_label":"ISSUER","cik":"0001826457","name":"Monte Rosa Therapeutics, Inc.","url":"/issuer/0001826457","role":"Ten percent owner","n_filings":4,"first_seen":"2021-06-30","last_seen":"2024-10-30"},{"type":"issuer","type_label":"ISSUER","cik":"0001701541","name":"Black Diamond Therapeutics, Inc.","url":"/issuer/0001701541","role":"Ten percent owner","n_filings":16,"first_seen":"2020-02-05","last_seen":"2024-08-30"},{"type":"issuer","type_label":"ISSUER","cik":"0001544227","name":"Tempest Therapeutics, Inc.","url":"/issuer/0001544227","role":"Ten percent owner","n_filings":1,"first_seen":"2024-08-12","last_seen":"2024-08-12"},{"type":"issuer","type_label":"ISSUER","cik":"0001850119","name":"Century Therapeutics, Inc.","url":"/issuer/0001850119","role":"Ten percent owner","n_filings":2,"first_seen":"2021-06-23","last_seen":"2022-08-11"},{"type":"issuer","type_label":"ISSUER","cik":"0001808158","name":"Repare Therapeutics Inc.","url":"/issuer/0001808158","role":"Ten percent owner","n_filings":2,"first_seen":"2020-06-25","last_seen":"2022-06-07"},{"type":"issuer","type_label":"ISSUER","cik":"0001720725","name":"Oyster Point Pharma, Inc.","url":"/issuer/0001720725","role":"Ten percent owner","n_filings":2,"first_seen":"2019-11-04","last_seen":"2021-10-20"},{"type":"issuer","type_label":"ISSUER","cik":"0001799448","name":"Aligos Therapeutics, Inc.","url":"/issuer/0001799448","role":"Ten percent owner","n_filings":1,"first_seen":"2020-10-20","last_seen":"2020-10-20"},{"type":"issuer","type_label":"ISSUER","cik":"0001744659","name":"Akero Therapeutics, Inc.","url":"/issuer/0001744659","role":"Ten percent owner","n_filings":11,"first_seen":"2019-06-25","last_seen":"2020-07-10"},{"type":"issuer","type_label":"ISSUER","cik":"0001787297","name":"Passage BIO, Inc.","url":"/issuer/0001787297","role":"Ten percent owner","n_filings":1,"first_seen":"2020-03-03","last_seen":"2020-03-03"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001687880","retrieved_at":"2026-08-23T02:09:14+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}